Intervention

PD-0332991

ClinicalTrials.gov intervention label

Clinical trials4
Recruiting0
Common conditions25
Lead sponsors shown2

Clinical trials

4 shown
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)NCT01740427 · 2013-02-22
COMPLETED
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast CancerNCT01684215 · 2012-10-19
COMPLETED
Relative Bioavailability StudyNCT01602887 · 2012-05-01
COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerNCT01037790 · 2009-10-01
COMPLETED

Common conditions

Breast Neoplasms2Adenocarcinoma of the Colon1Adenocarcinoma of the Rectum1Adult Central Nervous System Germ Cell Tumor1Adult Solid Tumor1Adult Teratoma1Benign Teratoma1Estrogen Receptor-negative Breast Cancer1Estrogen Receptor-positive Breast Cancer1Familial Testicular Germ Cell Tumor1Healthy1HER2-negative Breast Cancer1HER2-positive Breast Cancer1Male Breast Cancer1Neoplasms1Ovarian Immature Teratoma1Ovarian Mature Teratoma1Ovarian Monodermal and Highly Specialized Teratoma1Progesterone Receptor-negative Breast Cancer1Progesterone Receptor-positive Breast Cancer1Recurrent Breast Cancer1Recurrent Colon Cancer1Recurrent Extragonadal Germ Cell Tumor1Recurrent Extragonadal Non-seminomatous Germ Cell Tumor1Recurrent Extragonadal Seminoma1

Trial status mix

COMPLETED4

Phase mix

PHASE22
PHASE11
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.